Funding for this research was provided by:
Stiftelsen Assar Gabrielssons Fond
Knut och Alice Wallenbergs Stiftelse
Lions Cancer Research Fund of Western Sweden
University of Gothenburg
Received: 10 November 2022
Accepted: 2 March 2023
First Online: 6 April 2023
: The study was approved by the Regional Ethical Review Board in Linköping, Sweden (registration number 2016/387-31) and the Regional Ethical Review Board in Gothenburg, Sweden (registration number 479-18).
: Not applicable.
: The authors SJ, EK, TZP, SN, MS and RAA declare no conflict of interest. PK reports Research Contract Prelude DX and PFS genomics and has advisory role in AstraZeneca. ROB has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag) and SkyLineDx, speaker honorarium from Roche, Pfizer and Pierre-Fabre, and has served on advisory boards for Amgen, BD/BARD, Bristol-Myer Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme, and is as shareholder in SATMEG Ventures AB. AK has received honorarium from Roche, MSD and Pfizer and is a member of the Advisory Board of Pfizer.